Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Bernstein SocGen Group raised its price target on Natera (NASDAQ:NTRA) to $205.00 from $200.00 on Friday, while maintaining an Outperform rating on the genetic testing company’s stock. Currently trading at $141.08, Natera has shown strong momentum with a 31% return over the past year, according to InvestingPro data.
The price target adjustment follows Natera’s reported total revenues of $547 million, which exceeded consensus estimates of $476 million by 15%. The company has demonstrated impressive revenue growth of 51.5% over the last twelve months, with total revenue reaching $1.83 billion. InvestingPro analysis reveals 8 additional key insights about Natera’s financial performance.
Natera posted gross margins of 63.4% reported, or 60.4% on a repeatable basis when excluding a 3 percentage point true-up benefit, which fell below consensus estimates of 61.3%.
The company has raised its revenue guidance to a range of $2,020-$2,100 million for the current fiscal year.
Natera maintained its operating expense guidance unchanged despite the revenue outlook increase, according to Bernstein SocGen.
In other recent news, Natera reported its second-quarter 2025 earnings, revealing a strong revenue performance that exceeded expectations. The company announced a revenue of $546.6 million, surpassing forecasts by 14.85%, though its earnings per share (EPS) came in at -$0.74, missing the anticipated -$0.62. Despite the EPS miss, the market responded favorably, likely due to the robust revenue growth. Following the earnings announcement, TD Cowen raised its price target for Natera from $200 to $215, maintaining a Buy rating on the stock. This adjustment reflects the company’s strong performance across key metrics. These recent developments have generated positive sentiment around Natera, as evidenced by the stock’s upward movement in response to the earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.